Arca
Skip to content
Tools
Tools

POL: Human immunodeficiency virus type 1 reverse transcriptase

Protein in Human immunodeficiency virus 1 that 31 drugs act on.

  • Drugs that act on it: 31
  • Approved: 15
  • In phases 1 to 3: 16
  • Sponsors: 16

Who is on it, and how far along

Every drug ChEMBL records acting on POL, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 31

Approved15

  • Tenofovir disoproxil
  • Tenofovir alafenamide
  • Emtricitabine
  • Lamivudine
  • Rilpivirine
  • Zalcitabine
  • Doravirine
  • Abacavir
  • Efavirenz
  • Zidovudine
  • Nevirapine
  • Etravirine
  • Delavirdine
  • Didanosine
  • Stavudine

Phase 35

  • Islatravir
  • Dapivirine
  • Apricitabine
  • RO-0622
  • Tenofovir anhydrous

Phase 211

  • Amdoxovir
  • Atevirdine mesylate
  • Bilr 355
  • Capravirine
  • Censavudine
  • Dexelvucitabine
  • Elvucitabine
  • Emivirine
  • Lersivirine
  • Rovafovir etalafenamide
  • Tenofovir exalidex

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 30 of 31 act as: Human immunodeficiency virus type 1 reverse transcriptase inhibitor; the rest name their own mechanism.
    Tenofovir disoproxilBoxed warningApprovedGilead SciencesSmall moleculeInhibitor160
    Tenofovir alafenamideBoxed warningApprovedGilead SciencesSmall moleculeInhibitor96
    EmtricitabineApprovedGilead SciencesSmall moleculeInhibitor83
    LamivudineBoxed warningApprovedViiV HealthcareSmall moleculeInhibitor64
    RilpivirineApprovedJohnson & JohnsonSmall moleculeInhibitor39
    ZalcitabineBoxed warningApprovedRocheSmall moleculeInhibitor34
    DoravirineApprovedMerck & Co. (MSD)Small moleculeNegative allosteric modulatorHuman immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator23
    AbacavirBoxed warningApprovedViiV HealthcareSmall moleculeInhibitor15
    EfavirenzApprovedBristol-Myers SquibbSmall moleculeInhibitor14
    ZidovudineBoxed warningApprovedViiV HealthcareSmall moleculeInhibitor10
    NevirapineBoxed warningApprovedBoehringer Ingelheim PharmaceuticalsSmall moleculeInhibitor6
    EtravirineApprovedJohnson & JohnsonSmall moleculeInhibitor3
    DelavirdineApprovedViiV HealthcareSmall moleculeInhibitor2
    DidanosineBoxed warningApprovedBristol-Myers SquibbSmall moleculeInhibitor2
    StavudineBoxed warningApprovedBristol-Myers SquibbSmall moleculeInhibitor2
    IslatravirPhase 3Merck & Co. (MSD)Small moleculeInhibitor12
    DapivirinePhase 3International Partnership for Microbicides, Inc.Small moleculeInhibitor5
    ApricitabinePhase 3AvexaSmall moleculeInhibitor0
    RO-0622Phase 3Shanghai Henlius BiotechSmall moleculeInhibitor0
    Tenofovir anhydrousPhase 3Hepatera Ltd.Small moleculeInhibitor0
    AmdoxovirPhase 2RFS Pharma, LLCSmall moleculeInhibitor0
    Atevirdine mesylatePhase 2PfizerSmall moleculeInhibitor0
    Bilr 355Phase 2Boehringer Ingelheim PharmaceuticalsSmall moleculeInhibitor0
    CapravirinePhase 2PfizerSmall moleculeInhibitor0
    CensavudinePhase 2Bristol-Myers SquibbSmall moleculeInhibitor0
    DexelvucitabinePhase 2IncyteSmall moleculeInhibitor0
    ElvucitabinePhase 2AstraZeneca PharmaceuticalsSmall moleculeInhibitor0
    EmivirinePhase 2Bristol-Myers SquibbSmall moleculeInhibitor0
    LersivirinePhase 2PfizerSmall moleculeInhibitor0
    Rovafovir etalafenamidePhase 2Gilead SciencesSmall moleculeInhibitor0
    Tenofovir exalidexPhase 2ContraVir Pharmaceuticals, Inc.Small moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 59 in all, from ClinicalTrials.gov.
    Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis BTenofovir alafenamide, Tenofovir disoproxilPhase 1Not yet recruitingXiamen Amoytop Biotech Co., Ltd.Nov 18, 2026
    An Evaluation of the Potential for VH4011499 Drug-drug-interactionsEfavirenzPhase 1Not yet recruitingViiV HealthcareNov 16, 2026
    People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for EffectivenessEmtricitabine, Rilpivirine, Tenofovir alafenamide, Tenofovir disoproxilPhase 1Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)Nov 16, 2026
    Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir AlafenamideEmtricitabine, Tenofovir alafenamide, Tenofovir disoproxil—RecruitingCentre de Recherches et d'Etude sur la Pathologie Tropicale et le SidaNov 6, 2026
    Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIVEmtricitabine, Rilpivirine, Tenofovir alafenamide, Tenofovir disoproxilPhase 4Not yet recruitingGilead SciencesNov 2, 2026
    Starting HIV Prevention Medicine (PrEP) During an Emergency Department Visit With a Peer NavigatorEmtricitabine, Tenofovir disoproxilPhase 4Not yet recruitingUniversity of South FloridaOct 28, 2026
    Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy - The RELAI StudyRilpivirinePhase 4Not yet recruitingUniversity of North Carolina, Chapel HillOct 26, 2026
    Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIVDoravirine, Emtricitabine, Lamivudine, Tenofovir alafenamide, Tenofovir disoproxil, IslatravirPhase 2Not yet recruitingThe University of Texas Health Science Center, HoustonOct 13, 2026
    DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kgDoravirine, IslatravirPhase 2Not yet recruitingMerck Sharp & Dohme LLCOct 7, 2026
    Study on Retention in Care and on Clinical Chracteristics of HIV-infected Women Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIKWO).Emtricitabine, Tenofovir alafenamide, Tenofovir disoproxil—Not yet recruitingEnte Ospedaliero Ospedali GallieraOct 6, 2026
    Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus LevelsEmtricitabine, Tenofovir alafenamide, Tenofovir disoproxilPhase 2RecruitingGilead SciencesSep 25, 2026
    A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)LamivudinePhase 2Not yet recruitingViiV HealthcareSep 11, 2026
    Tenofovir Exposures in Advanced Kidney Disease StudyEmtricitabine, Tenofovir alafenamide—Not yet recruitingKing's College Hospital NHS TrustSep 10, 2026
    An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaAbacavir, Lamivudine, ZalcitabinePhase 3Not yet recruitingUniversity College, LondonAug 28, 2026
    Optimization of Antiretroviral Therapy in Patients With AIDS-Related LymphomaRilpivirineNot applicableRecruitingShanghai Public Health Clinical CenterJul 27, 2026
    Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.Rilpivirine—Active, not recruitingFUNDACIÓN HOSPITAL UNIVERSITARIO INFANTA LEONOR Y DEL HOSPITAL UNIVERSITARIO DEL SURESTEJul 14, 2026
    Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyRilpivirinePhase 3RecruitingGilead SciencesJul 6, 2026
    Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upLamivudine, ZalcitabinePhase 4RecruitingInstituto Mexicano del Seguro SocialJul 1, 2026
    Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIVDoravirine, Lamivudine, ZalcitabinePhase 4Not yet recruitingUniversity of Witwatersrand, South AfricaJun 29, 2026
    A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedRilpivirinePhase 3RecruitingViiV HealthcareJun 16, 2026
    Lamivudine as a Novel Clinical Effort for Rett SyndromeLamivudine, ZalcitabinePhase 2Enrolling by invitationMaria Denise Fernandes Carvalho de AndradeJun 10, 2026
    Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical StudyRilpivirinePhase 2RecruitingBeijing 302 HospitalJun 10, 2026
    Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir RegimensEfavirenz, Lamivudine, ZalcitabinePhase 4Not yet recruitingShanghai Public Health Clinical CenterJun 8, 2026
    Dolutegravir/Lamivudine in Treatment-Naïve Pregnant WomenLamivudine, ZalcitabinePhase 4RecruitingFundación HuéspedJun 1, 2026
    Drug-Drug Interactions of JMKX003142 in Healthy ParticipantsEfavirenzPhase 1Not yet recruitingJemincareMay 4, 2026
    Preliminary Testing and Development of a Short Digital Intervention for Patients on Waiting Lists for Psychological TreatmentAbacavirNot applicableEnrolling by invitationUniversity of OsloMar 30, 2026
    Efavirenz for the Treatment of Creutzfeldt-Jakob DiseaseEfavirenzPhase 3RecruitingXuanwu Hospital, BeijingMar 19, 2026
    A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentZalcitabinePhase 3RecruitingViiV HealthcareFeb 6, 2026
    Efficacy and Safety of Doravirine in the Rapid InitiationDoravirine, ZalcitabinePhase 4RecruitingFundación HuéspedJan 22, 2026
    A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy ParticipantsEfavirenzPhase 1Not yet recruitingSunshine Lake Pharma Co., Ltd.Jan 14, 2026
    A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)IslatravirPhase 2 / Phase 3RecruitingMerck Sharp & Dohme LLCDec 5, 2025
    Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-UpAbacavirPhase 4RecruitingJosé Antonio Mata MarínAug 22, 2025
    Patient-reported Outcomes (PRO) and Treatment Outcomes of Chinese Patients With MSS-type Advanced Colorectal Cancer Who Received the Zidovudine Combination Regimen in the Real WorldZidovudine—RecruitingWest China HospitalAug 6, 2025
    Research on the Psychological Status of Patients With HIV-1 InfectionAbacavir, Efavirenz, Nevirapine, Zidovudine—Not yet recruitingShanxi Bethune HospitalJul 23, 2025
    DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or ObesityDoravirinePhase 3RecruitingJosé Antonio Mata MarínJul 20, 2025
    Multi-product PrEP Delivery to Young Women Seeking Reproductive Health Services and Coverage of HIV PreventionDapivirinePhase 4RecruitingUniversity of Alabama at BirminghamJul 20, 2025
    Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in PakistanAbacavirNot applicableRecruitingPakistan Institute of Living and LearningJun 11, 2025
    Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic DermatitisZidovudinePhase 2RecruitingNovartis PharmaceuticalsApr 27, 2025
    STI Testing to Enhance PrEP Use in PregnancyDapivirinePhase 3RecruitingBotswana Harvard AIDS Institute PartnershipApr 9, 2025
    A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)IslatravirPhase 2Active, not recruitingMerck Sharp & Dohme LLCMar 24, 2025
    The T Cell Activator of Cell Killing ("TACK") IT ON" STUDYEfavirenzNot applicableRecruitingUniversity of TorontoFeb 12, 2025
    PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.Dapivirine—RecruitingDesmond Tutu HIV FoundationFeb 4, 2025
    Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH SuccessfullyDoravirinePhase 2RecruitingCentre de Recherches et d'Etude sur la Pathologie Tropicale et le SidaJan 14, 2025
    Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1Abacavir, Doravirine, IslatravirPhase 3Active, not recruitingGilead SciencesOct 8, 2024
    Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1IslatravirPhase 3Active, not recruitingGilead SciencesOct 8, 2024
    PrEP My Way: A Hybrid Type 1 Clinical Effectiveness-implementation Trial to Promote PrEP Persistence Among Young Kenyan WomenDapivirineNot applicableRecruitingMassachusetts General HospitalAug 22, 2024
    STARLITE for Unresectable High-Grade GliomasAbacavirPhase 1RecruitingUniversity of MiamiMay 24, 2024
    Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus ErythematosusAbacavirPhase 2Not yet recruitingHospices Civils de LyonApr 10, 2024
    Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV VirusesDoravirine, Efavirenz, EtravirinePhase 2Not yet recruitingANRS, Emerging Infectious DiseasesApr 1, 2024
    A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsDidanosine, Nevirapine, Stavudine, ZidovudinePhase 4RecruitingGilead SciencesMar 29, 2024
    Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTDapivirinePhase 3RecruitingAfrica Health Research InstituteFeb 9, 2024
    B-free Multistage TrialEtravirinePhase 4Enrolling by invitationInsel Gruppe AG, University Hospital BernSep 14, 2023
    A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)IslatravirPhase 3Active, not recruitingMerck Sharp & Dohme LLCMar 13, 2023
    DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)IslatravirPhase 3Active, not recruitingMerck Sharp & Dohme LLCJan 30, 2023
    Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Delavirdine, Nevirapine, ZidovudinePhase 2 / Phase 3Active, not recruitingGilead SciencesAug 16, 2022
    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell LymphomaZidovudinePhase 2Active, not recruitingNational Cancer Institute (NCI)Apr 22, 2019
    Early Infant HIV Treatment in BotswanaNevirapine, ZidovudinePhase 2 / Phase 3Active, not recruitingHarvard School of Public Health (HSPH)Feb 24, 2015
    Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionNevirapinePhase 1 / Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)May 16, 2014
    Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVDelavirdine, Didanosine, Etravirine, Nevirapine, Stavudine, ZidovudinePhase 2 / Phase 3Active, not recruitingGilead SciencesDec 20, 2013

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL247, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.